check out bio SRPT today.…it soared.. the FDA might approve their drug on only phase 2 data, for Duchenne Muscular Dystrophy. SRPT now has a $1.33 BILLION market cap. Oddly enough, the neuro patent that was granted to RGRX a handful of months ago, specifically included…….Duchenne Mujscular Dystrophy. Here it is:
" Duchenne muscular dystrophy (DMD) is one of a group of muscular dystrophies characterized by the enlargement of muscles. DMD is one of the most prevalent types of muscular dystrophy and is characterized by rapid progression of muscle degeneration that occurs early in life. All are X-linked and affect mainly males--an estimated 1 in 3500 boys worldwide. "
That is from RGRX's issued patent. if you want to read the patent application….search this number: